File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Acute effect of orlistat on post-prandial lipaemia and free fatty acids in overweight patients with Type 2 diabetes mellitus

TitleAcute effect of orlistat on post-prandial lipaemia and free fatty acids in overweight patients with Type 2 diabetes mellitus
Authors
KeywordsFree fatty acids
Lipase inhibitor
Triglyceride
Triglyceride-rich lipoprotein remnants
Type 2 diabetes mellitus
Issue Date2002
PublisherBlackwell Publishing Ltd. The Journal's web site is located at http://www.blackwellpublishing.com/journals/DME
Citation
Diabetic Medicine, 2002, v. 19 n. 11, p. 944-948 How to Cite?
AbstractAims: Post-prandial lipaemia is prolonged and exaggerated in patients with Type 2 diabetes mellitus, with an accumulation of atherogenic triglyceride-rich lipoprotein remnants. We postulate that orlistat, a gastrointestinal lipase inhibitor, may cause changes in post-prandial lipoprotein metabolism by reducing dietary triglyceride absorption. Methods: The acute effect of a single dose of 120 mg orlistat on post-prandial glucose, lipids, remnant lipoproteins and free fatty acids (FFA) was evaluated in a randomized, double-blind, placebo-controlled cross-over study of 63 overweight patients with Type 2 diabetes mellitus (body mass index 30.4 ± 3.8 kg/m2). Either a single dose of orlistat or placebo was given before a standard mixed meal containing 70 g of fat and plasma triglyceride (TG), remnant-like particles cholesterol (RLP-C) and FFA were sampled at 2-h intervals for 8 h. RLP-C was measured by an immunoseparation assay and FFA by an enzymatic colorimetric method. Results: The concentrations of plasma TG (P < 0.0001), RLP-C (P = 0.003), and FFA (P < 0.0001) were significantly lower at 2 h after orlistat compared with placebo. Both plasma RLP-C (P = 0.04) and FFA (P < 0.0001) remained lower after orlistat than placebo at 4 h. The incremental area under the curve (iAUC) above baseline fasting level for both TG and RLP-C was significantly more reduced after orlistat than placebo (iAUC-TG 5.8 (3.7-8.2) mmol/l × h-1 vs. 5.7 (4.1-10.9), respectively, P = 0.04; iAUC-RLP-C: 0.53 (0.23-1.04) mmol/l × h-1 vs. 0.56 (0.35-1.40), respectively, P = 0.02). The test meal was well tolerated by all subjects, with only three subjects reporting faecal urgency after orlistat. Conclusions: Orlistat has a beneficial effect on post-prandial lipaemia in overweight Type 2 diabetic patients and lowers plasma TG, RLP-C and FFA in the early post-prandial period.
Persistent Identifierhttp://hdl.handle.net/10722/78188
ISSN
2015 Impact Factor: 3.152
2015 SCImago Journal Rankings: 1.654
ISI Accession Number ID
References

 

DC FieldValueLanguage
dc.contributor.authorTan, KCBen_HK
dc.contributor.authorTso, AWKen_HK
dc.contributor.authorTam, SCFen_HK
dc.contributor.authorPang, RWCen_HK
dc.contributor.authorLam, KSLen_HK
dc.date.accessioned2010-09-06T07:40:08Z-
dc.date.available2010-09-06T07:40:08Z-
dc.date.issued2002en_HK
dc.identifier.citationDiabetic Medicine, 2002, v. 19 n. 11, p. 944-948en_HK
dc.identifier.issn0742-3071en_HK
dc.identifier.urihttp://hdl.handle.net/10722/78188-
dc.description.abstractAims: Post-prandial lipaemia is prolonged and exaggerated in patients with Type 2 diabetes mellitus, with an accumulation of atherogenic triglyceride-rich lipoprotein remnants. We postulate that orlistat, a gastrointestinal lipase inhibitor, may cause changes in post-prandial lipoprotein metabolism by reducing dietary triglyceride absorption. Methods: The acute effect of a single dose of 120 mg orlistat on post-prandial glucose, lipids, remnant lipoproteins and free fatty acids (FFA) was evaluated in a randomized, double-blind, placebo-controlled cross-over study of 63 overweight patients with Type 2 diabetes mellitus (body mass index 30.4 ± 3.8 kg/m2). Either a single dose of orlistat or placebo was given before a standard mixed meal containing 70 g of fat and plasma triglyceride (TG), remnant-like particles cholesterol (RLP-C) and FFA were sampled at 2-h intervals for 8 h. RLP-C was measured by an immunoseparation assay and FFA by an enzymatic colorimetric method. Results: The concentrations of plasma TG (P < 0.0001), RLP-C (P = 0.003), and FFA (P < 0.0001) were significantly lower at 2 h after orlistat compared with placebo. Both plasma RLP-C (P = 0.04) and FFA (P < 0.0001) remained lower after orlistat than placebo at 4 h. The incremental area under the curve (iAUC) above baseline fasting level for both TG and RLP-C was significantly more reduced after orlistat than placebo (iAUC-TG 5.8 (3.7-8.2) mmol/l × h-1 vs. 5.7 (4.1-10.9), respectively, P = 0.04; iAUC-RLP-C: 0.53 (0.23-1.04) mmol/l × h-1 vs. 0.56 (0.35-1.40), respectively, P = 0.02). The test meal was well tolerated by all subjects, with only three subjects reporting faecal urgency after orlistat. Conclusions: Orlistat has a beneficial effect on post-prandial lipaemia in overweight Type 2 diabetic patients and lowers plasma TG, RLP-C and FFA in the early post-prandial period.en_HK
dc.languageengen_HK
dc.publisherBlackwell Publishing Ltd. The Journal's web site is located at http://www.blackwellpublishing.com/journals/DMEen_HK
dc.relation.ispartofDiabetic Medicineen_HK
dc.rightsDiabetic Medicine. Copyright © Blackwell Publishing Ltd.en_HK
dc.subjectFree fatty acidsen_HK
dc.subjectLipase inhibitoren_HK
dc.subjectTriglycerideen_HK
dc.subjectTriglyceride-rich lipoprotein remnantsen_HK
dc.subjectType 2 diabetes mellitusen_HK
dc.subject.meshAdulten_HK
dc.subject.meshAnti-Obesity Agents - therapeutic useen_HK
dc.subject.meshCholesterol - blooden_HK
dc.subject.meshCross-Over Studiesen_HK
dc.subject.meshDiabetes Mellitus - drug therapyen_HK
dc.subject.meshDiabetes Mellitus, Type 2 - blood - drug therapy - enzymologyen_HK
dc.subject.meshDietary Fats - metabolismen_HK
dc.subject.meshDouble-Blind Methoden_HK
dc.subject.meshEnzyme Inhibitors - therapeutic useen_HK
dc.subject.meshFatty Acids, Nonesterified - blooden_HK
dc.subject.meshFemaleen_HK
dc.subject.meshHumansen_HK
dc.subject.meshHyperlipidemias - drug therapyen_HK
dc.subject.meshLactones - therapeutic useen_HK
dc.subject.meshLipase - blooden_HK
dc.subject.meshLipoproteins - blooden_HK
dc.subject.meshMaleen_HK
dc.subject.meshMiddle Ageden_HK
dc.subject.meshObesityen_HK
dc.subject.meshPostprandial Period - drug effectsen_HK
dc.subject.meshTriglycerides - blooden_HK
dc.titleAcute effect of orlistat on post-prandial lipaemia and free fatty acids in overweight patients with Type 2 diabetes mellitusen_HK
dc.typeArticleen_HK
dc.identifier.openurlhttp://library.hku.hk:4550/resserv?sid=HKU:IR&issn=0742-3071&volume=19&issue=11&spage=944&epage=8&date=2002&atitle=Acute+effect+of+orlistat+on+post-prandial+lipaemia+and+free+fatty+acids+in+overweight+patients+with+type+2+diabetes+mellitusen_HK
dc.identifier.emailTan, KCB: kcbtan@hku.hken_HK
dc.identifier.emailTso, AWK: awk.tso@gmail.comen_HK
dc.identifier.emailPang, RWC: robertap@hku.hken_HK
dc.identifier.emailLam, KSL: ksllam@hku.hken_HK
dc.identifier.authorityTan, KCB=rp00402en_HK
dc.identifier.authorityTso, AWK=rp00535en_HK
dc.identifier.authorityPang, RWC=rp00274en_HK
dc.identifier.authorityLam, KSL=rp00343en_HK
dc.description.naturelink_to_subscribed_fulltext-
dc.identifier.doi10.1046/j.1464-5491.2002.00823.xen_HK
dc.identifier.pmid12421432-
dc.identifier.scopuseid_2-s2.0-0036432963en_HK
dc.identifier.hkuros78711en_HK
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-0036432963&selection=ref&src=s&origin=recordpageen_HK
dc.identifier.volume19en_HK
dc.identifier.issue11en_HK
dc.identifier.spage944en_HK
dc.identifier.epage948en_HK
dc.identifier.isiWOS:000179565300009-
dc.publisher.placeUnited Kingdomen_HK
dc.identifier.scopusauthoridTan, KCB=8082703100en_HK
dc.identifier.scopusauthoridTso, AWK=6701371436en_HK
dc.identifier.scopusauthoridTam, SCF=7202037323en_HK
dc.identifier.scopusauthoridPang, RWC=7004376659en_HK
dc.identifier.scopusauthoridLam, KSL=8082870600en_HK

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats